Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR) gapped up prior to trading on Monday . The stock had previously closed at $0.34, but opened at $0.37. Ritter Pharmaceuticals shares last traded at $0.38, with a volume of 2,495,242 shares trading hands.
A number of equities research analysts recently issued reports on the stock. Zacks Investment Research cut shares of Ritter Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, August 8th. HC Wainwright dropped their price target on shares of Ritter Pharmaceuticals from $7.00 to $1.50 and set a “buy” rating on the stock in a research note on Monday, October 23rd. Chardan Capital dropped their price target on shares of Ritter Pharmaceuticals from $3.50 to $1.50 and set a “buy” rating on the stock in a research note on Tuesday, August 8th. Maxim Group reissued a “hold” rating on shares of Ritter Pharmaceuticals in a research note on Wednesday, July 5th. Finally, Roth Capital set a $2.00 price target on shares of Ritter Pharmaceuticals and gave the company a “buy” rating in a research note on Monday, October 23rd. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. Ritter Pharmaceuticals has an average rating of “Buy” and a consensus target price of $2.92.
The firm’s market cap is $5.59 million. The stock has a 50 day moving average of $0.43 and a 200 day moving average of $0.43.
Ritter Pharmaceuticals (NASDAQ:RTTR) last posted its earnings results on Monday, August 7th. The biotechnology company reported ($0.14) earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.14). Equities analysts forecast that Ritter Pharmaceuticals, Inc. will post ($0.42) earnings per share for the current year.
An institutional investor recently raised its position in Ritter Pharmaceuticals stock. KCG Holdings Inc. raised its position in Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR) by 259.0% during the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 105,409 shares of the biotechnology company’s stock after purchasing an additional 76,046 shares during the period. KCG Holdings Inc. owned about 0.91% of Ritter Pharmaceuticals worth $150,000 at the end of the most recent reporting period. 2.25% of the stock is owned by institutional investors.
COPYRIGHT VIOLATION NOTICE: “Ritter Pharmaceuticals, Inc. (RTTR) Shares Gap Up to $0.37” was posted by Community Financial News and is the sole property of of Community Financial News. If you are accessing this story on another publication, it was illegally copied and reposted in violation of U.S. and international copyright and trademark legislation. The legal version of this story can be read at https://www.com-unik.info/2017/10/30/ritter-pharmaceuticals-inc-rttr-shares-gap-up-to-0-37.html.
Ritter Pharmaceuticals Company Profile
Ritter Pharmaceuticals, Inc develops therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. The Company’s segment is focusing on the development and commercialization of RP-G28. The Company conducts human gut health research by exploring metabolic capacity of the gut microbiota and translating the functionality of prebiotic-based therapeutics into applications intended to have impact on a patient’s health.
What are top analysts saying about Ritter Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Ritter Pharmaceuticals Inc. and related companies.